LIFE:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund Hedged Units (CAD)

ETF | Sector Equity |

Last Closing

CAD 22.7

Change

-0.01 (-0.04)%

Market Cap

CAD 0.01B

Volume

1.58K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-27 )

Largest Industry Peers for Sector Equity

Symbol Name Price(Change) Market Cap
TEC:CA TD Global Technology Leaders I..

+0.39 (+1.01%)

CAD 2.66B
ZWU:CA BMO Covered Call Utilities ETF

+0.10 (+0.91%)

CAD 1.90B
XHC:CA iShares Global Healthcare (CAD..

-0.02 (-0.03%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

+0.11 (+0.20%)

CAD 0.61B
TXF:CA First Asset Tech Giants Covere..

+0.06 (+0.28%)

CAD 0.60B
HTA:CA Harvest Tech Achievers Growth ..

+0.14 (+0.77%)

CAD 0.59B
ZUT:CA BMO Equal Weight Utilities Ind..

+0.38 (+1.77%)

CAD 0.44B
CWW:CA iShares Global Water Common Cl..

+0.40 (+0.70%)

CAD 0.33B
XUT:CA iShares S&P/TSX Capped Utiliti..

+0.52 (+1.88%)

CAD 0.30B
COW:CA iShares Global Agriculture Com..

+0.38 (+0.63%)

CAD 0.28B

ETFs Containing LIFE:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Sector Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.19% 53% F 48% F
Dividend Return 1.54% 63% D 44% F
Total Return 10.73% 53% F 50% F
Trailing 12 Months  
Capital Gain 5.53% 29% F 34% F
Dividend Return 1.49% 50% F 32% F
Total Return 7.02% 29% F 34% F
Trailing 5 Years  
Capital Gain 16.23% 24% F 48% F
Dividend Return 6.48% 44% F 22% F
Total Return 22.71% 18% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain 0.99% N/A N/A 43% F
Dividend Return 2.13% N/A N/A 41% F
Total Return 1.14% N/A N/A 39% F
Risk Return Profile  
Volatility (Standard Deviation) 6.97% N/A N/A 80% B-
Risk Adjusted Return 30.53% N/A N/A 51% F
Market Capitalization 0.01B 9% A- 8% B-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.